Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk Cover

.blurhash-client-img { display: none !important; }

Anti-inflammatory and immunomodulatory effects of rosuvastatin in patients with low-to-moderate cardiovascular risk

Acta Pharmaceutica

Volume 72 (2022): Issue 2 (June 2022)

By: ANA VAVLUKIS, MARIJA VAVLUKIS, ALEKSANDAR DIMOVSKI, GORDANA PETRUSHEVSKA, ALEKSANDAR EFTIMOV, SASHKA DOMAZETOVSKA and KRISTINA MLADENOVSKA

Open Access

|Dec 2021

Authors

ANA VAVLUKIS

ana.vavlukis@gmail.com

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia

MARIJA VAVLUKIS

University Ss Cyril and Methodius Faculty of Medicine, Skopje, RN Macedonia

ALEKSANDAR DIMOVSKI

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia

GORDANA PETRUSHEVSKA

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia

ALEKSANDAR EFTIMOV

University Ss Cyril and Methodius Faculty of Medicine, Skopje, RN Macedonia

SASHKA DOMAZETOVSKA

University Ss Cyril and Methodius Faculty of Medicine, Skopje, RN Macedonia

KRISTINA MLADENOVSKA

University Ss Cyril and Methodius Faculty of Pharmacy, Skopje, RN Macedonia

DOI: https://doi.org/10.2478/acph-2022-0018 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075

Journal RSS Feed

Language: English

Page range: 303 - 315

Accepted on: Jun 21, 2021

|

Published on: Dec 30, 2021

Published by: Croatian Pharmaceutical Society

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

vascular endothelial growth factor,

epidermal growth factor,

cardiovascular risk

Related subjects:

Pharmacy, other

© 2021 ANA VAVLUKIS, MARIJA VAVLUKIS, ALEKSANDAR DIMOVSKI, GORDANA PETRUSHEVSKA, ALEKSANDAR EFTIMOV, SASHKA DOMAZETOVSKA, KRISTINA MLADENOVSKA, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous article Volume 72 (2022): Issue 2 (June 2022)Next article